2Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [ J ]. Science, 2004, 304(5676) : 1497 - 1500.
3Yamaguchi M, Matsumoto T, Tate G,'et al. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene [ J ]. J Gastroenterol, 2004, 39(9): 904-905.
4Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EG- FR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer [J]. Lancet Oncol, 2008, 9(10): 962-972.
5Konner J, Schilder R J, DeRosa F A, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer[ J]. Gynecol Oncol, 2008, 110(2) : 140 -145.
6Robert F, Blumenschein G, Herbst R S, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer[ J]. J Clin Oncol, 2005, 23 (36) : 9089 - 9096.
7Fukuoka M, Yano S, Giaccone G, etal. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nun-small-cell lung cancer ( The IDEAL 1 Trial) [ J ]. J Clin Oncol, 2003, 21 (12) : 2237-2246.
8Nimeiri H S, Oza A M, Morgan R J, etal. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia[ J]. Gynecol Oncol, 2008, 110(1 ) : 49 - 55.
9Zhu X, Wu S, Dahut W L, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis[ J ]. Am J Kidney Dis, 2007, 49(2) : 186 -193.
10Costa D B, Kobayashi S, Tenen D G, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers[J]. Lung Cancer, 2007, 58(1): 95-103.
